The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Phase III HD17 trial update: the prognostic value of PET in HL
Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, discusses an investigation within the Phase III HD17 trial (NCT01356680) of the prognostic impact of PET status on progression-free survival (PFS) in patients with Hodgkin lymphoma (HL) previously treated with 2+2 chemotherapy. The study of over 900 patients found that in early-stage unfavorable HL, a positive PET scan represents a risk factor for PFS, particularly when a Deauville score (DS) of 4 is considered as the cutoff for positivity. Since bulky disease after chemotherapy is a risk factor for DS4, further research is needed into early identification of these high-risk patients in order to improve the treatment strategy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
